Canada recently became the first G7 country to approve a generic version of the widely used diabetes and weight-loss medication Ozempic, reducing costs significantly for patients, according to Reuters and BBC News. The regulatory approval marks a major shift in the global market for glucagon-like peptide-1 medications, though patients in the United States will have to wait several years for similar relief.
Elizabeth Doran, a 69-year-old resident of Ottawa, has been taking GLP-1 medications for nearly a year. Her doctor prescribed Wegovy to help reverse her prediabetes and lower her high blood pressure. Since she had not yet developed full type 2 diabetes, she did not qualify for the provincial drug coverage offered to diabetic seniors in Ontario. She told the BBC that she was just one decimal point away from being officially diabetic.
Without public insurance coverage, the medication forced a heavy financial burden on the retired teacher. Doran paid between 350 and 500 Canadian dollars out of pocket every month. To afford the prescription, she took on substitute teaching shifts multiple times a month and searched for discount cards offered by the manufacturer, Novo Nordisk. With the arrival of generic alternatives, patients like Doran will no longer have to hunt for bargains or take on extra work to afford essential treatments.
Health Canada formally authorized generic semaglutide injections in May. The regulatory body approved versions produced by India-based Dr. Reddy`s Laboratories and Canadian pharmaceutical company Apotex. While officially indicated for type 2 diabetes, doctors frequently prescribe the drug off-label for weight management. These discounted medications are already hitting pharmacy shelves nationwide, priced at less than a third of the brand-name cost.
The introduction of generic options will make these drugs accessible to the three million Canadians who currently use them, as well as many others previously priced out of the market. The increased competition has already pressured Novo Nordisk to lower the prices of its brand-name products. A similar situation unfolded in India earlier this year when the approval of dozens of low-cost versions forced Novo Nordisk to cut Ozempic and Wegovy prices by nearly 50 percent there.
Patients in the United States face a drastically different landscape. Uninsured Americans routinely pay upwards of 1,000 dollars a month for Ozempic. An estimated 15 million adults in the United States currently take GLP-1 medications, and low-cost alternatives remain years away due to stringent drug patent laws that allow pharmaceutical companies to maintain their monopolies.
Erez Israeli, chief executive officer of Dr. Reddy`s, told the BBC that his company has applied for generic approval in more than 80 countries. While he expects the generic GLP-1 to soon reach markets across South America, Africa, and Asia, it will not be available in the United States, the United Kingdom, or Europe anytime soon. Apotex has secured tentative approval from the US Food and Drug Administration, but it cannot legally sell its generic semaglutide there yet.
Tahir Amin, founder of the US-based advocacy group Initiative for Medicines, Access and Knowledge, explained that American and European regulations allow companies to extend patents for several years to compensate for regulatory delays. As a result, Americans will not see a generic version until at least 2032, when the primary compound patent protecting semaglutide expires.
Novo Nordisk originally held a patent in Canada that could have been extended until 2028, but the company failed to pay a minor 250-dollar maintenance fee to renew it. What remains unclear is whether this was an administrative oversight or a calculated business decision. Amin suggested the company dropped the ball, enabling generics to enter Canada sooner. Novo Nordisk dismissed this theory, stating the Canadian generic introduction was a localized situation based on specific patent timelines that does not reflect their intact exclusivity in the United States.
Industry experts anticipate a surge of Americans attempting to access the low-cost generic Ozempic from Canada. Cross-border pharmaceutical shopping has an extensive history, highlighted by the 2019 caravans of Americans traveling north to purchase cheaper insulin. In 2023, the province of British Columbia restricted Americans from purchasing Ozempic after discovering that 15 percent of prescriptions were being exported across the border.
